Bruton tyrosine kinase inhibitors for multiple sclerosis
Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …
worsening of disability, which is assumed to be mainly associated with transient infiltration of …
B cells in multiple sclerosis—from targeted depletion to immune reconstitution therapies
MT Cencioni, M Mattoscio, R Magliozzi… - Nature Reviews …, 2021 - nature.com
Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …
involves demyelination and axonal degeneration. Although substantial progress has been …
Rituximab for the treatment of multiple sclerosis: a review
CG Chisari, E Sgarlata, S Arena, S Toscano, M Luca… - Journal of …, 2022 - Springer
In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …
B cells in autoimmune and neurodegenerative central nervous system diseases
B cells are essential components of the adaptive immune system and have important roles
in the pathogenesis of several central nervous system (CNS) diseases. Besides producing …
in the pathogenesis of several central nervous system (CNS) diseases. Besides producing …
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy
F Aloisi, G Giovannoni, M Salvetti - The Lancet Neurology, 2023 - thelancet.com
Multiple sclerosis is a chronic inflammatory disease of the CNS that results from the interplay
between heritable and environmental factors. Mounting evidence from different fields of …
between heritable and environmental factors. Mounting evidence from different fields of …
Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments
AM Weideman, MA Tapia-Maltos, K Johnson… - Frontiers in …, 2017 - frontiersin.org
Objective To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical
trials, to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies …
trials, to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies …
Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders
C Kaegi, B Wuest, J Schreiner, UC Steiner… - Frontiers in …, 2019 - frontiersin.org
Background: During the past years biologic agents (also termed biologicals or biologics)
have become a crucial treatment option in immunological diseases. Numerous articles have …
have become a crucial treatment option in immunological diseases. Numerous articles have …
A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future
Background Multiple sclerosis (MS) is a chronic and autoimmune disease of the central
nervous system (CNS), mainly characterized by inflammatory demyelination, which …
nervous system (CNS), mainly characterized by inflammatory demyelination, which …
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
F Piehl - Journal of Internal Medicine, 2021 - Wiley Online Library
The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …
demyelinating and neurodegenerative disease of the central nervous system (CNS) …